Clinical Trials Logo

Clinical Trial Summary

This study evaluates the safety and tolerability of escalating doses of BP1002 (Liposomal Bcl-2 Antisense Oligodeoxynucleotide) in patients with refractory/relapsed AML. The study is designed to assess the safety profile, identify DLTs, biologically effective doses, PK, PD and potential anti-leukemic effects of BP1002 as single agent (dose escalation phase) followed by assessing BP1002 in combination with decitabine (dose expansion phase).

Clinical Trial Description


Study Design

Related Conditions & MeSH terms

NCT number NCT05190471
Study type Interventional
Source Bio-Path Holdings, Inc.
Contact Michael Hickey
Phone 832-742-1361
Email [email protected]
Status Not yet recruiting
Phase Phase 1
Start date January 2022
Completion date September 2024

See also
  Status Clinical Trial Phase
Active, not recruiting NCT02204085 - A Phase I/II Trial of the MUC1 Inhibitor, GO-203-2C in Patients With Relapsed or Refractory Acute Myeloid Leukemia Phase 1/Phase 2
Recruiting NCT05105152 - PLAT-08: A Study Of SC-DARIC33 In Pediatric And Young Adults With Relapsed Or Refractory CD33+ AML Phase 1
Recruiting NCT04898894 - Study of Selinexor and Venetoclax in Combination With Chemotherapy in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia Phase 1
Recruiting NCT04402541 - Study of CB-5339 in Acute Myeloid Leukemia or Myelodysplastic Syndrome Phase 1
Recruiting NCT03690154 - A Phase 1 Study to Evaluate FN-1501 Monotherapy in Patients With Advanced Solid Tumors and R/R AML Phase 1
Recruiting NCT03957915 - Study of Escalating Doses of INA03 Administered Intravenously as Single Agent in Adult Patients With Relapse/Refractory Acute Leukemia Early Phase 1
Not yet recruiting NCT04867928 - Venetoclax and Azacitidine for the Management of Molecular Relapse/Progression in Adult NPM1-mutated Acute Myeloid Leukemia Phase 2
Completed NCT04321161 - Analysis of T Cell Metabolism in Relapsed AML Patients With DLIs and Bicanorm Treatment Early Phase 1
Recruiting NCT04678336 - CD123 Redirected T Cells for AML in Pediatric Subjects Phase 1
Not yet recruiting NCT04716452 - Study of C6 Ceramide NanoLiposome (CNL) in Patients With Relapsed/Refractory Acute Myeloid Leukemia Phase 1
Not yet recruiting NCT03053206 - A Prospective, Interventional Study Assessing Response to Cytarabine, Daunorubicin and Etoposide (ADE) for First Relapse of Paediatric Acute Myeloid Leukemia Phase 2
Active, not recruiting NCT03766126 - Lentivirally Redirected CD123 Autologous T Cells in AML Phase 1
Terminated NCT02353143 - Study of MEN1112 Intravenous Infusion in Relapsed or Refractory Acute Myeloid Leukemia Phase 1
Not yet recruiting NCT05124288 - Analysis of the Immunobiology of Acute Myeloid Leukemia Relapses After Allogeneic Hematopoietic Stem Cell Transplant (HSCT) for the Generation of Guidelines and Personalized Therapeutic Pathways
Terminated NCT02438761 - PF-05212384 (PKI-587) for t-AML/MDS or de Novo Relapsed or Refractory Acute Myeloid Leukemia (AML) Phase 2
Recruiting NCT04914845 - KPT-9274 in Patients With Relapsed and Refractory Acute Myeloid Leukemia Phase 1
Active, not recruiting NCT02768792 - High Dose Cytarabine Followed by Pembrolizumab in Relapsed/Refractory AML Phase 2
Not yet recruiting NCT03116477 - Study Investigating the Efficacy of the Addition of Crenolanib to Chemotherapy vs Chemotherapy Alone in Patients With R/R FLT3 Mutated AML Phase 3